WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2003059256) GENES OVEREXPRESSES BY OVARIAN CANCER AND THEIR USE IN DEVELOPING NOVEL THERAPEUTICS ESPECIALLY ANTIBODIES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2003/059256    International Application No.:    PCT/US2002/040861
Publication Date: 24.07.2003 International Filing Date: 23.12.2002
Chapter 2 Demand Filed:    14.07.2003    
IPC:
C12Q 1/68 (2006.01)
Applicants: IDEC PHARMACEUTICALS CORPORATION [US/US]; 3030 Callan Road, San Diego, CA 92121 (US) (For All Designated States Except US).
MCLACHLAN, Karen [US/US]; (US) (For US Only).
REFF, Mitchell [US/US]; (US) (For US Only).
DANIELS, Mark [US/US]; (US) (For US Only)
Inventors: MCLACHLAN, Karen; (US).
REFF, Mitchell; (US).
DANIELS, Mark; (US)
Agent: TESKIN, Robin, L.; Pillsbury Winthrop LLP, 1600 Tysons Boulevard, McLean, VA 22102 (US).
CAWLEY, Thomas, A., Jr.; Pillsbury Winthrop LLP, 1600 Tysons Boulevard, McLean, VA 22102 (US)
Priority Data:
60/341,860 21.12.2001 US
Title (EN) GENES OVEREXPRESSES BY OVARIAN CANCER AND THEIR USE IN DEVELOPING NOVEL THERAPEUTICS ESPECIALLY ANTIBODIES
(FR) GENES SUREXPRIMES PAR LE CANCER DE L'OVAIRE ET LEUR UTILISATION DANS L'ELABORATION DE NOUVELLES THERAPIES NOTAMMENT DES ANTICORPS
Abstract: front page image
(EN)Nucleic acid sequences encoding genes that are overexpressed by human ovarian cancers are provided. These genes and the corresponding antigens are useful diagnostic and therapeutic targets. The invention provides cancer therapies that target these antigens, especially using monoclonal antibodies that target the Anat-2 antigen.
(FR)La présente invention concerne des séquences d'acide nucléique codant pour des gènes qui sont surexprimés par les cancers de l'ovaire humains. Lesdits gènes et les antigènes correspondants constituent des cibles utiles en diagnostic et en thérapeutique. L'invention concerne également des traitement thérapeutiques du cancer ciblant ces antigènes, notamment en utilisant des anticorps monoclonaux qui ciblent l'antigène Anat-2.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)